Anti-Viral Drug Market
Global Anti-Viral Drug Market Size, Share, and Trends Analysis Report, by Type (Generic Anti-Viral Drugs and Branded Anti-Viral Drugs), by Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), by Application (HIV, Hepatitis, Herpes Virus, Influenza, and Others), Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global anti-viral drug market is anticipated to grow at a CAGR of 4.0% during the forecast period. The growing prevalence of numerous infectious diseases such as HIV, Hepatitis, Herpes Virus, COVID-19, Ebola, and seasonal influenza globally is one of the major factors increasing the demand for anti-viral drugs. In 2019, an estimated 1.2 million people in the US aged 13 and older had HIV, as per HIV.gov estimates. The demand for anti-viral drugs has surged since the time of the COVID-19 pandemic. Many organizations had been working towards the development of anti-viral drugs and therapeutics for COVID-19 at the time of the pandemic, which leads to the high drug development and that has further affected the market positively. For instance, in 2020, NIAID partnering NIH Institutes and initiated an intensive research program to prioritize and accelerate the development of COVID-19 therapeutics. The research program was enhanced through the APP’s discovery and development initiatives. Under which APP focused on the development of antivirals that directly act against viral targets, specifically for RNA viruses including SARS-COV-2, Paramyxoviridae, Bunyavirales, Picornaviridae, Filoviridae, Togaviridae, and Flaviviridae.
Moreover, ongoing R&D activities and private investments in healthcare infrastructure development along with the introduction of new and effective anti-viral drugs are further expected to impel market growth. Supportive government investments to promote research and development for the treatment of viral infection is expected to bring lucrative opportunity for the market players to develop novel drugs and therapeutics targeting viral infection. However, the high cost associated with some of the anti-viral hepatitis drugs is the prime concern limiting their wide production.
Segmental Outlook
The global anti-viral drug market is segmented based on type, mechanism of action, and application. Based on type, the market is sub-segmented into generic anti-viral drugs and branded anti-viral drugs. Further, the global anti-viral drug market is divided based on the mechanism of action into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Among these, reverse transcriptase inhibitors will show remarkable growth. Reverse transcriptase inhibitor is classified: as nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). The availability of these reverse transcriptase inhibitors which are broadly used in antiretroviral therapy is the key factor that has boosted their demand and will help in segment growth during the forecast period.
Based on application, the market is categorized into HIV, hepatitis, herpes virus, influenza, and others. The HIV segment is expected to hold the highest share due to increasing hepatitis disease prevalence globally. As per the Minority HIV/AIDS Fund, there were approximately 37.7 million people across the globe with HIV in 2020. Of these, 36 million were adults and 1.7 million were children aged 0-14 years. The prevalence is expected to increase with time and create scope for the anti-viral drug further as these drugs allow the immune system to repair itself and prevent further damage from HIV.
Regional Outlook
Geographically, the global anti-viral drug market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). The North American anti-viral drug market is set to display progressive growth during the expected time frame. The factors contributing to the growth of the regional market include a well-established healthcare infrastructure and the presence of the major players offering innovative antiviral drugs in the market. In addition, the FDA approval of the new drugs and effective therapies will further aid in the market expansion on a broad level. Whereas the presence of favorable reimbursement policies in Europe is expected to bring new growth opportunities to the market, which in turn will help to grow more.
Global Anti-Viral Drug Market Growth by Region, 2022-2028
Asia-Pacific Emerged as a Fastest Growing Region in Anti-Viral Drug Market
The Asia-Pacific region has the largest population base affected by HIV, Hepatitis, Influenza, and other viral diseases. Around 5.8 million people are living with HIV in Asia-Pacific major economies. The Philippines has become the country with the fastest-growing HIV epidemic and has become one of eight countries that account for more than 85% of new HIV infections in the region. There were 6000 confirmed HIV-positive individuals reported to the HIV/AIDS & ART Registry of the Philippines (HARP) in 2021. The presence of an established generic drug market and increasing health awareness in the region motivate people to get access to the drugs helping in better health and well-being. Moreover, the government-sponsored awareness program about generic medicine in the Asia-Pacific region is one of the major drivers of antiviral drug market growth.
Market Players Outlook
The major market players in the global anti-viral drug market include AbbVie, Inc., Merck & Co., GlaxoSmithKline plc, Pfizer Inc., Mylan NV, Dr. Reddy’s Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals Ltd., Strides Pharma Science Ltd., Upsher-Smith Laboratories, among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in March 2022, AbbVie collaborated with Scripps Research, an independent, non-profit biomedical research and drug discovery institute to develop a potential novel, direct-acting antiviral treatment for COVID-19. The collaboration will bring brings AbbVie’s both scientific expertise and manufacturing capabilities to accelerate the development of the potential novel.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global anti-viral drug market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Porter’s Analysis
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Anti-Viral Drug Market by Type
4.1.1. Generic Anti-Viral Drugs
4.1.2. Branded Anti-Viral Drugs
4.2. Global Anti-Viral Drug Market by Mechanism of Action
4.2.1. Nucleotide Polymerase Inhibitor
4.2.2. Reverse Transcriptase Inhibitors
4.2.3. Protease Inhibitors
4.2.4. Others
4.3. Global Anti-Viral Drug Market by Application
4.3.1. HIV
4.3.2. Hepatitis
4.3.3. Herpes Virus
4.3.4. Influenza
4.3.5. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
5.4.1. Latin America
5.4.2. Middle East & Africa
6. Company Profiles
6.1. AbbVie, Inc.
6.2. Abbott Laboratories
6.3. Arbutus Biopharma Corp.
6.4. Aurobindo Pharma, Ltd.
6.5. BioCryst Pharmaceuticals, Inc.
6.6. Bristol-Myers Squibb Co.
6.7. Candel Therapeutics, Inc.
6.8. Cipla, Inc.
6.9. Dr. Reddy’s Laboratories, Ltd.
6.10. F. Hoffmann-La Roche AG
6.11. Gilead Sciences, Inc.
6.12. GlaxoSmithKline PLC
6.13. Johnson & Johnson Services, Inc.
6.14. Merck & Co., Inc.
6.15. Mylan N.V.
6.16. Pfizer, Inc.
6.17. Sanofi S.A.
6.18. Sino Biopharmaceutical, Ltd.
6.19. The Hep B Company
6.20. Zydus Lifesciences, Ltd.
1. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
5. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
11. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL PROTEASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL OTHER MECHANISM OF ACTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
19. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
20. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
21. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
24. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
29. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
31. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
32. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
2. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY MECHANISM OF ACTION, 2021 VS 2028 (%)
3. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
4. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
5. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
6. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET SHARE BY REGION, 2021 VS 2028 (%)
8. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET SHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET SHARE BY REGION, 2021 VS 2028 (%)
10. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
12. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET SHARE BY REGION, 2021 VS 2028 (%)
13. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
14. GLOBAL PROTEASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
15. GLOBAL OTHER MECHANISM OF ACTION MARKET SHARE BY REGION, 2021 VS 2028 (%)
16. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
17. US ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. CANADA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. UK ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. FRANCE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. GERMANY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. ITALY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. SPAIN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF EUROPE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. INDIA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. CHINA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. JAPAN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. SOUTH KOREA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF ASIA-PACIFIC ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
